Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LZM 012

Next Previous
X
Search
Drug Profile

LZM 012

Alternative Names: LZM-012

Latest Information Update: 06 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Livzon Pharmaceuticals
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Psoriasis
  • Phase II Immunological disorders

Most Recent Events

  • 08 Nov 2023 LZM 012 is available for licensing as of 08 Nov 2023. https://en.livzon.com.cn/intro/57.html
  • 21 Aug 2023 Phase-III clinical trials in Psoriasis in China (SC) (NCT06110676)
  • 27 Jun 2023 Livzon Pharmaceuticals has patent protection for anti-IL-17 antibodies in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top